Core Insights - Cardinal Health is hosting an Investor Day to discuss growth strategies and long-term financial outlook [2][3] - The company emphasizes its strong foundation and significant future growth opportunities [3] Strategic Updates - Cardinal Health is focusing on expanding its Pharmaceutical and Specialty Solutions, particularly in Specialty and higher-margin businesses [4] - The Specialty Alliance platform will include the recently acquired GI Alliance and the new Urology Alliance [5] - The MSO platforms now support approximately 2,200 providers across 28 states [6] Biopharma Solutions - Continued investments in Biopharma Solutions are announced, with expansions into oncology and other therapeutic areas [7] - The Sonexus™ Access and Patient Support platform is expected to more than double its supported therapies by fiscal year 2028 [7] Pharmaceutical Distribution - The Consumer Health Logistics Center in Ohio is set to be fully operational by July 2025, aimed at increasing capacity and efficiency [8] - Plans for a new forward distribution center with advanced automation technology are underway [9] Financial Guidance - FY25 non-GAAP diluted EPS guidance is raised to $8.15 to $8.20, with preliminary FY26 guidance set at $9.10 to $9.30 [10][18] - Long-term targets for non-GAAP diluted EPS growth are set at 12% to 14% for FY26 to FY28 [20] Capital Deployment - The company plans to invest at least $600 million annually in capital expenditures and anticipates at least $750 million in share repurchases each year for the next three years [21]

Core Insights - Global Technologies, LTD (GTLL) is undergoing a strategic pivot towards digital health and wellness, driven by recent FDA regulatory changes impacting the industry [2][5] - The company has launched a new subsidiary, Primecare Supply, LLC, and entered into key commercial agreements to enhance its position in compliant pharmaceutical distribution and digital wellness innovation [3][5] Company Developments - GTLL has officially launched Primecare Supply, LLC, and executed two significant commercial agreements that will position the company at the forefront of the industry [3] - The company has appointed H. Wyatt Flippen as Chairman of the Board and CEO, while removing the President of its clean energy subsidiary to focus on core operations [4] Strategic Focus - The company aims to build a leaner and more focused business aligned with FDA-compliant pharmaceutical distribution and digital wellness innovation [5] - GTLL is expanding its offerings in consumer-facing wellness plans and therapeutic products, leveraging traditional partnerships and digital infrastructure [5] Financial Agreements - On May 19, 2025, Primecare entered into a Revenue Share Agreement with a licensed pharmaceutical supplier, retaining 75% of gross margin revenue above the supplier's floor price [8] - On May 28, 2025, Primecare signed a Master Licensing Agreement with an AI technology partner, which includes a platform fee of 2.5% of processed transactions for a 24-month term [8]

Core Insights - McKesson Corporation reported fourth-quarter fiscal 2025 adjusted EPS of $10.12, exceeding the Zacks Consensus Estimate of $9.81 by 3.2%, and showing a year-over-year increase of 63.8% [1] - The company's revenue for the quarter was $90.82 billion, which missed the Zacks Consensus Estimate by 3.1%, but represented an 18.9% increase year-over-year, driven by strong performance in the Pharmaceutical segment, particularly in specialty products and oncology [2][5] Revenue and Segment Performance - U.S. Pharmaceutical segment revenues reached $83.2 billion, up 21% year-over-year, primarily due to increased prescription volumes and growth in the oncology platform [5] - The International segment reported revenues of $3.5 billion, down 2% year-over-year, attributed to the divestiture of the Canada-based Rexall and Well.ca retail businesses, although higher pharmaceutical distribution volumes partially offset this decline [8] - Medical-Surgical Solutions segment revenues totaled $2.9 billion, up 1% year-over-year, driven by higher volumes of specialty pharmaceuticals [9] - Prescription Technology Solutions segment revenues were $1.3 billion, reflecting a 14% year-over-year increase due to growth in technology services and third-party logistics [10] Profitability and Margins - Gross profit for the quarter was $3.39 billion, up 2.2% year-over-year, representing 3.7% of net revenues, a decrease of nearly 60 basis points year-over-year [12] - Adjusted operating income was $1.72 billion, an 18.5% increase from the prior year, with an operating margin of 1.9%, remaining flat year-over-year [12] Strategic Initiatives and Future Outlook - McKesson announced plans to separate its Medical-Surgical Solutions segment into an independent company to enhance strategic opportunities [10] - The company provided EPS guidance of $36.75-$37.55 for fiscal 2026 but did not offer total and segmental sales outlook due to the potential spin-off [14] - McKesson is investing in advanced technologies, including AI and data analytics, to improve operational efficiency and patient care outcomes [18] - The company emphasized its commitment to health equity and expanding access to pharmacies in underserved areas [18] Market Performance - McKesson's shares rose 2.3% in after-hours trading on May 8, reflecting positive bottom-line performance and plans for divestiture [4] - Year-to-date, McKesson's shares have gained 21.1%, contrasting with a 1.6% decline in the industry and a 4.9% decline in the S&P 500 Index [4]

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion [6][42] - Adjusted earnings per diluted share was $33.05, exceeding expectations with a year-over-year growth of 20% [6][45] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth [35][36] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment revenues increased 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty products [36] - The Prescription Technology Solutions segment saw revenues increase 13% to $1.3 billion, with operating profit rising 34% to $285 million [37] - The Medical Surgical Solutions segment revenues increased 1% to $2.9 billion, with operating profit up 15% to $285 million [39] Market Data and Key Metrics Changes - Revenues from GLP-1 medications in the fourth quarter were $10.9 billion, a 46% increase compared to the prior year [36] - The Canadian business, part of the international segment, experienced a 2% revenue decrease due to divestitures, but operating profit increased 9% [40][60] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of Prism Vision and Core Ventures [7][12] - A decision was announced to separate the Medical Surgical segment into an independent company to enhance strategic focus and capital deployment [20][29] - The company aims to leverage technology, automation, and AI to improve operational efficiencies and enhance financial profiles [9][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue momentum and deliver strong results in fiscal 2026, anticipating revenue growth of 11% to 15% [46][66] - The company is closely monitoring the macroeconomic environment and potential impacts from policy changes, but remains optimistic about the healthcare industry's resilience [26][100] - Management emphasized the importance of community-based care and its role in managing healthcare costs and accessibility [72] Other Important Information - The company returned $3.5 billion to shareholders, including $3.1 billion through share repurchases [45] - Free cash flow for the fiscal year was $5.2 billion, driven by strong operational results [45][41] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no confirmed changes and emphasized the importance of community-based care in managing costs [69][72] Question: Tariff Impacts on Business - Management is monitoring the tariff landscape but does not anticipate a material impact on fiscal 2026 guidance [78][85] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [90][93] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in guidance reflects a stable environment for prescription utilization and successful capital deployment [97][101] Question: SG&A Efficiency Improvements - Management acknowledged a substantial decline in SG&A expenses year-over-year, attributing it to operational efficiencies [105]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]

McKesson Corporation Fiscal 2025 Financial Results Fiscal 2026 Outlook May 8, 2025 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimat ...

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure within its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, compared to $10-$30 for standard bank wires [7] Market Trends - XRP is gaining traction among global institutions, with CME Group set to launch cash-settled XRP futures in May 2025 to meet institutional demand [6] - Mastercard has identified XRP as a bridge currency for cross-border payments, highlighting its efficiency and cost-effectiveness [7] Company Overview - Wellgistics Health operates across pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription hub services and aims to eliminate friction in the supply chain, enhancing reimbursement processes and creating transparent pathways [10]

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure across its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, enhancing operational efficiency [7] Market Positioning - Wellgistics Health is positioning itself to lead in the healthcare and fintech convergence by leveraging XRP, as evidenced by the growing institutional interest in XRP [6][8] - The company is focused on unlocking capital velocity and running operations more efficiently than its peers in the pharmaceutical infrastructure space [6] Industry Trends - XRP is gaining traction with major institutions, including the CME Group launching XRP futures and Mastercard identifying XRP as a bridge currency for cross-border payments [6][7] - Ripple's recent acquisitions and regulatory advancements further solidify XRP's role in the financial services landscape [8] Company Overview - Wellgistics Health operates in pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription services and aims to streamline the medication supply chain by reducing friction and accelerating reimbursements [10]

Cencora (COR) is slated to report second-quarter fiscal 2025 results on May 7, before market open. In the last reported quarter, the company delivered an earnings surprise of 6.57%. COR's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.(Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $74.82 billion, up 9.4% from the prior-year quarter's level. The consensus ma ...